Printer Friendly

BIO-RAD INTRODUCES TEST FOR H. PYLORI BACTERIA THAT CAUSES MANY ULCERS

 HERCULES, Calif., April 14 /PRNewswire/ -- Bio-Rad Laboratories Inc. (AMEX: BIO.A; BIO.B) announced the introduction of a new clinical assay for the H. pylori bacteria called the Bio-Rad GAP(TM) ELISA. David Schwartz, president of the Company, said, "There has been a great deal of interest in this test following a number of recent studies linking ulcers and H. pylori. With an estimated 18 million people in the United States alone suffering from gastric and peptic ulcers, the potential for this test to improve the diagnosis of ulcers and the monitoring of their treatment is tremendous."
 For many years it was believed that ulcers were caused by stress, poor diet and excess production of stomach acids. While these factors can aggravate ulcers, they do not actually cause them. According to a number of studies, many ulcers are caused by the bacteria Helicobacter pylori, commonly referred to as H. pylori.
 Previously, the presence of H. pylori was detected by examining tissue specimens from the lining of the stomach. However, blood serum tests, like the Bio-Rad GAP ELISA, now represent a better methodology. As a result, more and more physicians are using these tests as an alternative to costly, uncomfortable, time-consuming and sometimes unreliable stomach tissue biopsies.
 Along with the discovery that many ulcers are caused by bacterial infections has come a simple treatment. It consists of a combination of antibiotics, together with a substance called bismuth, which is also used in stomach medications like Pepto-Bismol(R). In a recent study on patients with duodenal ulcers, this form of treatment resulted in a marked reduction in the rate of recurrence. The Bio-Rad GAP ELISA test is also used to monitor this antibacterial therapy, and to measure its success in eradicating H. pylori.
 Bio-Rad Laboratories is a multinational manufacturer of life science research products, clinical diagnostics and analytical instruments based in Hercules.
 -0- 4/14/93
 /CONTACT: James L. Viglienzone, treasurer of Bio-Rad, 510-724-5697/
 (BIO.A BIO.B)


CO: Bio-Rad Laboratories Inc. ST: California IN: MTC SU:

LH-CK -- SF006 -- 5517 04/14/93 08:08 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 14, 1993
Words:344
Previous Article:MAGMA POWER CO. SELECTED BY PHILIPPINES NATIONAL OIL CO. TO BUILD AND OPERATE 70 MEGAWATT GEOTHERMAL POWER PLANT
Next Article:OFFICETEAM SURVEY FINDS ADMINISTRATIVE ASSISTANTS CARRY GREATER CLOUT; 'SECRETARIES DAY' MAY NEED NEW NAME AS JOB TITLE BECOMES OUTMODED
Topics:


Related Articles
ULCER CURE LINKED TO COMMON BACTERIUM; ULCER PATIENTS SHOULD INQUIRE ABOUT TEST FOR H. PYLORI
BIOMERICA SIGNS CONTRACT FOR DISTRIBUTION OF ULCER TEST IN THE UNITED STATES AND CANADA
ULCER CURE LINKED TO TREATMENT OF COMMON BACTERIUM -- KEY TOPIC AT NATIONAL DIGESTIVE DISEASE WEEK
BIOMERICA H. PYLORI TEST SALES SHOULD BENEFIT FROM NIH ANNOUNCEMENT
BIOMERICA H. PYLORI TEST SALES SHOULD BENEFIT FROM NIH ANNOUNCEMENT
BIOMERICA H. PYLORI TEST SALES SHOULD BENEFIT FROM NIH ANNOUNCEMENT
QUIDEL SUBMITS FIRST ONE-STEP, WHOLE BLOOD, RAPID H. PYLORI TEST TO FDA
Biomerica Introduces 10 Minute Test for Ulcer Screening
Meridian Receives FDA Clearance To Market Whole Blood Test For Stomach Ulcers
OraVax Out-Licenses CagA H. pylori Antigen to Biomerica, Inc.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters